TransCode Therapeutics, Inc. filed an amendment to its original Form 8-K report with the SEC to correct an error regarding the voting outcomes of its 2024 Annual Meeting of Shareholders, which took place on June 13, 2024. The amendment clarified that not all proposals were approved by the shareholders. During the meeting, four director nominees were elected, and the Stock Plan Amendment Proposal and the Auditor Proposal were approved. However, the Reverse Stock Split Proposal was not passed, and the Adjournment Proposal was approved without a subsequent motion to adjourn the meeting. The detailed voting results for each proposal were disclosed, including the number of votes for, against, abstentions, and broker non-votes where applicable.

TransCode Therapeutics, Inc. filed an amendment to its original Form 8-K report with the SEC to correct an error regarding the voting outcomes of its 2024 Annual Meeting of Shareholders, which took place on June 13, 2024. The amendment clarified that not all proposals were approved by the shareholders. During the meeting, four director nominees were elected, and the Stock Plan Amendment Proposal and the Auditor Proposal were approved. However, the Reverse Stock Split Proposal was not passed, and the Adjournment Proposal was approved without a subsequent motion to adjourn the meeting. The detailed voting results for each proposal were disclosed, including the number of votes for, against, abstentions, and broker non-votes where applicable.